Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Lebret

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
European Urology|July 5, 2016
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerJ Alfred Witjes, Thierry Lebret, Eva M Compérat, et al.
BMC Cancer|July 17, 2016
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancerMathieu Rouanne, Julien Adam, Aïcha Goubar, et al.
World Journal of Urology|July 5, 2023
Late complications and 5 years outcomes of robotic partial nephrectomy in France: prospective assessment in the French Kidney Cancer Research Network (UroCCR 10)Gaëlle Margue, Alexandre Ingels, Karim Bensalah, et al.
Cell Reports|December 3, 2014
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypesAnne Biton, Isabelle Bernard-Pierrot, Yinjun Lou, et al.
Urologic Oncology|September 5, 2025
Peritoneal recurrence following nephrectomy for localized renal cancer: A multicenter European real-world analysis of incidence, pattern and treatment (PEMET study-UroCCR 124)Caroline Pettenati, Jean-Christophe Bernhard, Zine-Eddine Khene, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
Oncogene|March 22, 2023
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networksHélène Neyret-Kahn, Jacqueline Fontugne, Xiang Yu Meng, et al.
European Urology|July 31, 2014
The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic reviewHarman M Bruins, Erik Veskimae, Virginia Hernandez, et al.
European Urology|June 28, 2023
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated TumorsClarice S Groeneveld, Virginia Sanchez-Quiles, Florent Dufour, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
European Urology|July 5, 2016
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerJ Alfred Witjes, Thierry Lebret, Eva M Compérat, et al.
BMC Cancer|July 17, 2016
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancerMathieu Rouanne, Julien Adam, Aïcha Goubar, et al.
World Journal of Urology|July 5, 2023
Late complications and 5 years outcomes of robotic partial nephrectomy in France: prospective assessment in the French Kidney Cancer Research Network (UroCCR 10)Gaëlle Margue, Alexandre Ingels, Karim Bensalah, et al.
Cell Reports|December 3, 2014
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypesAnne Biton, Isabelle Bernard-Pierrot, Yinjun Lou, et al.
Urologic Oncology|September 5, 2025
Peritoneal recurrence following nephrectomy for localized renal cancer: A multicenter European real-world analysis of incidence, pattern and treatment (PEMET study-UroCCR 124)Caroline Pettenati, Jean-Christophe Bernhard, Zine-Eddine Khene, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
Oncogene|March 22, 2023
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networksHélène Neyret-Kahn, Jacqueline Fontugne, Xiang Yu Meng, et al.
European Urology|July 31, 2014
The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic reviewHarman M Bruins, Erik Veskimae, Virginia Hernandez, et al.
European Urology|June 28, 2023
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated TumorsClarice S Groeneveld, Virginia Sanchez-Quiles, Florent Dufour, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
Pageof 15